PubRank

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Clinical Trial ID NCT01454102

PubWeight™ 68.71‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01454102

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014 2.71
4 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
5 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
6 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
7 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
8 The role of B7 family molecules in hematologic malignancy. Blood 2012 1.47
9 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
10 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
11 Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013 1.39
12 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
13 Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2014 1.33
14 Control of the immune response by pro-angiogenic factors. Front Oncol 2014 1.26
15 Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016 1.24
16 Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016 1.24
17 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
18 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.21
19 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015 1.18
20 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
21 CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2015 1.15
22 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
23 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
24 Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Front Immunol 2015 0.98
25 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
26 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
27 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
28 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
29 Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol 2015 0.92
30 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
31 Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2016 0.90
32 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
33 Updates in the management of brain metastases. Neuro Oncol 2016 0.88
34 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
35 Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2013 0.87
36 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
37 Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013 0.85
38 Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer 2014 0.84
39 Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther 2016 0.82
40 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.82
41 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
42 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.80
43 Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol 2014 0.80
44 Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn 2016 0.80
45 Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 2015 0.80
46 The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2015 0.79
47 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
48 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
49 Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2014 0.78
50 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
51 Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res 2015 0.78
52 Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 2016 0.78
53 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
54 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
55 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014 0.75
56 Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology 2016 0.75
57 What does the future hold for immunotherapy in cancer? Ann Transl Med 2016 0.75
58 Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? Transl Lung Cancer Res 2016 0.75
59 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
60 Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016 0.75
Next 100